



Synta Pharmaceuticals to Present at the 9th Annual MASS Opportunities Investment Conference

November 5, 2007

Company to Webcast Presentation on November 8

LEXINGTON, Mass.--(BUSINESS WIRE)--Nov. 5, 2007--Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that the company will be presenting at the 9th Annual MASS Opportunities Investment Conference on Thursday, November 8, 2007 at 10:30 AM (ET) at the Hilton Logan Airport, Boston.

At the conference, President and CEO Safi Bahcall, Ph.D., will provide an update on the company's drug discovery and development programs, as well as a review of the recently announced transaction with GlaxoSmithKline. A live audio webcast and replay of the presentation will be available on the "Investors" section of the company's website, www.syntapharma.com.

About Synta Pharmaceuticals

Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. Synta has a unique chemical compound library, an integrated discovery engine, and a diverse pipeline of clinical- and preclinical-stage drug candidates with distinct mechanisms of action and novel chemical structures. All Synta drug candidates were discovered and developed internally. Synta has a global collaboration agreement with GlaxoSmithKline (GSK) for the joint development and commercialization of its lead investigational drug candidate, elesclomol. For more information, please visit www.syntapharma.com.

CONTACT: Synta Pharmaceuticals Corp.
Rob Kloppenburg, 781-541-7125
or
MacDougall Biomedical Communications
Doug MacDougall, 508-647-0209

SOURCE: Synta Pharmaceuticals Corp.